Related Experiment Video
Updated: Apr 15, 2026

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
p85α is a microRNA target and affects chemosensitivity in pancreatic cancer
Paul A Toste1, Luyi Li1, Brian E Kadera1
1Department of Surgery, Division of General Surgery, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Background:
We previously identified a correlation between increased expression of the phosphoinositide 3-kinase (PI3K) regulatory subunit p85α and improved survival in human pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate the impact of changes in p85α expression on response to chemotherapy and the regulation of p85α by microRNA-21 (miR-21).
Materials And Methods:
PDAC tumor cells overexpressing p85α were generated by viral transduction, and the effect of p85α overexpression on sensitivity to gemcitabine was tested by MTT assay. Primary human PDAC tumors were stained for p85α and miR-21 via immunohistochemistry and in situ hybridization, respectively. Additionally, PDAC cells were treated with miR-21 mimic, and changes in p85α and phospho-AKT were assessed by Western blot. Finally, a luciferase reporter assay system was used to test direct regulation of p85α by miR-21.
Results:
Higher p85α expression resulted in increased sensitivity to gemcitabine (P < 0.01), which correlated with decreased PI3K-AKT activation. Human tumors demonstrated an inverse correlation between miR-21 and p85α expression levels (r = -0.353, P < 0.001). In vitro, overexpression of miR-21 resulted in decreased levels of p85α and increased phosphorylation of AKT. Luciferase reporter assays confirmed the direct regulation of p85α by miR-21 (P < 0.01).
Conclusions:
Our results demonstrate that p85α expression is a determinant of chemosensitivity in PDAC. Additionally, we provide novel evidence that miR-21 can influence PI3K-AKT signaling via its direct regulation of p85α. These data provide insight into potential mechanisms for the known relationship between increased p85α expression and improved survival in PDAC.
Insights
Increased phosphoinositide 3-kinase (PI3K) p85α expression enhances pancreatic cancer sensitivity to chemotherapy. MicroRNA-21 directly regulates p85α, influencing PI3K-AKT signaling and potentially improving patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Pancreatic ductal adenocarcinoma (PDAC) survival is correlated with phosphoinositide 3-kinase (PI3K) regulatory subunit p85α expression.
- Understanding p85α's role in chemotherapy response and its regulation is crucial for PDAC treatment.
Purpose of the Study:
- To investigate the impact of p85α expression on pancreatic cancer response to chemotherapy.
- To elucidate the regulatory role of microRNA-21 (miR-21) in controlling p85α levels.
Main Methods:
- Generated PDAC cells overexpressing p85α for gemcitabine sensitivity testing (MTT assay).
- Utilized immunohistochemistry and in situ hybridization to analyze p85α and miR-21 expression in human PDAC tumors.
- Performed Western blot and luciferase reporter assays to confirm miR-21's direct regulation of p85α and its effect on PI3K-AKT signaling.
Main Results:
- Higher p85α expression significantly increased sensitivity to gemcitabine, correlating with reduced PI3K-AKT activation.
- A significant inverse correlation was observed between miR-21 and p85α expression in human PDAC tumors.
- In vitro, miR-21 overexpression decreased p85α levels and increased AKT phosphorylation, confirmed by luciferase assays.
Conclusions:
- p85α expression is a key determinant of chemosensitivity in pancreatic ductal adenocarcinoma.
- MicroRNA-21 directly regulates p85α, thereby influencing PI3K-AKT signaling pathways.
- These findings offer insights into the mechanisms linking elevated p85α expression to improved PDAC patient survival.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

